Pioglitazone

Pioglitazone

Drug monograph · NCLEX study reference
Trade names	Actos
Therapeutic class	Antidiabetic
Pharmacologic class	Thiazolidinedione
Onset / peak / duration	Glycemic effect over weeks.
Half-life / level	Half-life 3 to 7 hours (metabolites longer); no routine level.
Routes	PO (oral)
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	None; supportive.
Pregnancy / lactation	Generally avoided.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Pioglitazone (brand name Actos) — Antidiabetic; Thiazolidinedione.

Identification

• Therapeutic class: Antidiabetic.
• Pharmacologic class: Thiazolidinedione.

Pharmacology

• Mechanism of action: Activates PPAR-gamma to improve peripheral insulin sensitivity.
• Onset / peak / duration: Glycemic effect over weeks.
• Half-life / therapeutic level: Half-life 3 to 7 hours (metabolites longer); no routine level.

Clinical use

• Indications: Type 2 diabetes.
• Usual dose, route, frequency: 15 to 45 mg PO once daily.
• Maximum dose / adjustments: Max 45 mg/day; avoid in active liver disease.

Safety

• Contraindications: New York Heart Association class III to IV heart failure, active bladder cancer, severe hepatic impairment.
• Black box warning: May cause or worsen heart failure; not for symptomatic heart failure.
• Interactions: Insulin and sulfonylureas (hypoglycemia, edema), CYP2C8 inhibitors (gemfibrozil).
• Pregnancy / lactation: Generally avoided.
• High-alert: No.

Adverse effects

• Common side effects: Edema, weight gain, headache.
• Serious effects to report: Heart failure signs (edema, weight gain, dyspnea), fractures, possible bladder cancer, hepatotoxicity.
• Antidote / reversal: None; supportive.

Nursing process

• Assessment before administration: Heart failure status, LFTs, weight, edema.
• Interventions during therapy: Daily weights; assess for edema and dyspnea.
• Monitor: Weight, edema, LFTs, A1c, signs of heart failure.
• Evaluation / expected outcome: Improved glycemic control without fluid overload.

Patient teaching

• Patient teaching: Report rapid weight gain or swelling.
• Notify provider if: Swelling, shortness of breath, blood in urine, dark urine.
• Administration tips: With or without food.